In some studies these A/N/P negative tumors have been termed “triple negative,” while other studies have termed them neuroendocrine low SCLC with an “inflamed” gene signature “SCLC-I.” Importantly, retrospective stratification of patients with SCLC in the IMpower133 clinical trial demonstrates that patients with SCLC-I tumors show increased survival following chemoimmunotherapy with atezolizumab (anti-PD-L1) and etoposide, compared with SCLC-A, -N, or -P (13). The gene discussed is CD274; the disease is small cell lung carcinoma.